Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3323
Peer-review started: February 13, 2023
First decision: March 14, 2023
Revised: March 22, 2023
Accepted: April 4, 2023
Article in press: April 4, 2023
Published online: May 16, 2023
Processing time: 92 Days and 2.8 Hours
Left ventricular thrombus is a rare condition, for which appropriate treatments are not extensively studied. Although it can be treated by thrombectomy, such surgery can be difficult and risky, and not every patient can tolerate the surgery.
We report a case of a middle-aged man receiving veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for acute myocardial infarction who developed left ventricular thrombus despite systemic anticoagulation. After systemic thrombolysis with urokinase, the left ventricular thrombus disappeared, ECMO was successfully withdrawn 9 days later, and the patient recovered and was discharged from hospital.
Systemic thrombolysis is a treatment option for left ventricular thrombus in addition to anticoagulation and thrombectomy.
Core Tip: Urokinase is a useful medicine for thrombolysis. This is the first case report of urokinase administration for left ventricular thrombus occurring during veno-arterial extracorporeal membrane oxygenation therapy. Systemic thrombolytic therapy with urokinase can be considered when the effect of anticoagulant therapy is poor or the risk of surgical treatment is high after left ventricular thrombus formation.
